Features
Janice G. Inman
<b><I>Part One of a Two-Part Article</I></b><p>Analysis of a recent case in which a company, publicly accused by a plaintiff's lawyers of using non-FDA-approved medical devices, fought back by bringing a defamation suit against the opposing attorneys. The decision in the appeal offers some insights into what kinds of allegations may be publicized, and in what circumstances, when a product liability charge is brought.
Columns & Departments
ljnstaff
&
Law Journal Newsletters
A look at two interesting cases.
Features
Jonathan Friedland, Elizabeth Vandesteeg
&
Jeffrey Goldberg
Third-party litigation funding is a relatively new, but rapidly expanding litigation financing vehicle. According to the authors, general counsel and commercial litigators would be well served to understand the changing landscape regarding the scope and potential uses of such funding.
Features
Zach Warren
<b><i>With Massive Jury Rewards and the DTSA Encouraging Federal Litigation, Trade Secrets Litigation Is Seeing a Surge in the Tech Industry</b></i><p>These days, many of the big IP litigation battles involving companies like Facebook, Uber, and Epic, have nothing to do with patents, trademarks or copyrights at all. Instead, it's all about the perhaps forgotten part of IP: trade secrets.
Columns & Departments
Stan Soocher
Investment Firm Can Proceed Against Artist in Litigation Funding Dispute
Columns & Departments
ljnstaff
&
Law Journal Newsletters
A three-judge panel of the Second Circuit upheld the conviction of Mathew Martoma for insider trading and, in doing so, overruled part of <I>United States v. Newman</I>, thereby removing one obstacle for prosecutions of insider trading.
Columns & Departments
ljnstaff
&
Law Journal Newsletters
A look at a case in which, in a developer's article 78 proceeding challenging the town's denial of its application to rezone property, the town moved to dismiss.
Columns & Departments
ljnstaff
&
Law Journal Newsletters
In-depth analysis of two key rulings.
Columns & Departments
ljnstaff
&
Law Journal Newsletters
A look at a situation in which, because the drug-manufacturing defendants seeking federal retention of a case removed from state court were unable to prove the four elements of the U.S. Supreme Court's <I>Gunn</I> test for federal-question jurisdiction, the case was remanded back to state court.
Columns & Departments
ljnstaff
&
Law Journal Newsletters
Discussion of two major cases.
